• Explore /
  • Poster
  • / Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.

Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.

Abstract Video & Slides Poster

Authors

Meredith McKean

Meredith McKean

Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN

Meredith McKean , Anthony W. Tolcher , James Andrew Reeves , Bartosz Chmielowski , Montaser F. Shaheen , Joseph Thaddeus Beck , Marlana M. Orloff , Neeta Somaiah , Brian Andrew Van Tine , Joseph J. Drabick , Alexander I. Spira , Kenneth O'byrne , Christos Stelios Karapetis , Steven A. Foresto , Sujana Movva , Jose Martinez , Mingyu Li , Robert Winkler , Dajun Yang , Yifan Zhai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03611868

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9517)

DOI

10.1200/JCO.2022.40.16_suppl.9517

Abstract #

9517

Poster Bd #

110

Abstract Disclosures

Similar Posters

First Author: Montaser F. Shaheen

First Author: Anthony W. Tolcher

Poster

2019 ASCO Annual Meeting

A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.

A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.

First Author: Drew W. Rasco

First Author: Xing Zhang